Drug Type Small molecule drug |
Synonyms ANDRIGA-10, ANDRIGA-5, YONSA MPRED |
Target |
Action inhibitors, agonists |
Mechanism CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors), GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Australia (29 Mar 2022), |
Regulation- |
Molecular FormulaC26H33NO2 |
InChIKeyUVIQSJCZCSLXRZ-UBUQANBQSA-N |
CAS Registry154229-18-2 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hormone-dependent prostate cancer | Australia | 29 Mar 2022 | |
| Metastatic castration-resistant prostate cancer | Australia | 29 Mar 2022 |





